Document:

Exhibit 10.1

 

EXECUTION
COPY

 

AMENDMENT
NO. 1

 

Dated
as of June 25, 2015

 

to

 

CREDIT
AGREEMENT

 

Dated
as of April 30, 2014

 

THIS
AMENDMENT NO. 1 (this “Amendment”) is made as of June 25, 2015 by and among Aceto Corporation (the “Borrower”),
Aceto Agricultural Chemicals Corporation, Rising Pharmaceuticals, Inc. and Pack Pharmaceuticals, LLC (collectively with the Borrower,
the “Loan Parties”), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank,
N.A., as Administrative Agent (the “Administrative Agent”), under that certain Credit Agreement dated as of
April 30, 2014 by and among the Loan Parties, the Lenders and the Administrative Agent (as amended, restated, supplemented or
otherwise modified from time to time, the “Credit Agreement”). Capitalized terms used herein and not otherwise
defined herein shall have the respective meanings given to them in the Credit Agreement.

 

WHEREAS,
the Borrower has requested that the requisite Lenders and the Administrative Agent agree to certain amendments to the Credit Agreement;

 

WHEREAS,
the Loan Parties, the Lenders party hereto and the Administrative Agent have so agreed on the terms and conditions set forth herein;

 

NOW,
THEREFORE, in consideration of the premises set forth above, the terms and conditions contained herein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Loan Parties, the Lenders party hereto and the
Administrative Agent hereby agree to enter into this Amendment.

 

1.            Amendments
to the Credit Agreement. Effective as of the date of satisfaction of the conditions precedent set forth in Section 2
below, the parties hereto agree that the Credit Agreement is hereby amended as follows:

 

(a)          Section
1.01 of the Credit Agreement is amended to add the following definition thereto in the appropriate alphabetical order:

 

“Amendment
No. 1 Effective Date” means June 25, 2015.

 

(b)          The
definition of “Revolving Commitment” appearing in Section 1.01 of the Credit Agreement is amended to restate
the final sentence thereof in its entirety to read as follows:

 

The
aggregate amount of the Lenders’ Revolving Commitments as of the Amendment No. 1 Effective Date is $75,000,000.

 

    	 

    	 

    

 

(c)          Section
2.17 of the Credit Agreement is amended to add the following as a new clause (j) thereof: 

 

(j)          Certain
FATCA Matters. For purposes of determining withholding Taxes imposed under FATCA, from and after the Amendment No. 1 Effective
Date, the Borrower and the Administrative Agent shall treat (and the Lenders hereby authorize the Administrative Agent to treat)
this Agreement and the Loans as not qualifying as “grandfathered obligations” within the meaning of Treasury Regulation
Section 1.1471-2(b)(2)(i) or 1.1471-2T(b)(2)(i).

 

(d)          Schedule
2.01 to the Credit Agreement is amended and restated in its entirety in the form of Schedule 2.01 attached hereto as Annex
A.

 

2.            Conditions
of Effectiveness. The effectiveness of this Amendment is subject to the following conditions precedent:

 

(a)          The
Administrative Agent shall have received counterparts of this Amendment duly executed by the Loan Parties, the Lenders, the Issuing
Banks, the Swingline Lender and the Administrative Agent.

 

(b)          The
Administrative Agent shall have received a favorable written opinion (addressed to the Administrative Agent and the Lenders and
dated the effective date of this Amendment) of DLA Piper LLP, counsel for the Loan Parties, covering such matters relating to
the Loan Parties or the Credit Agreement (including the Credit Agreement as amended by this Amendment) as the Administrative Agent
shall reasonably request. The Borrower hereby requests such counsel to deliver such opinion.

 

(c)          The
Administrative Agent shall have received such documents and certificates as the Administrative Agent or its counsel may reasonably
request relating to the organization, existence and good standing of the Loan Parties, the authorization of this Amendment and
the Transactions and any other legal matters relating to such Loan Parties or the Credit Agreement (including the Credit Agreement
as amended by this Amendment), all in form and substance reasonably satisfactory to the Administrative Agent and its counsel.

 

(d)          The
Administrative Agent shall have received, for the account of each Lender party hereto that delivers its executed signature page
to this Amendment by no later than the date and time specified by the Administrative Agent, an upfront fee in an amount equal
to the amount previously agreed upon by the Borrower and disclosed to the Lenders.

 

(e)          The
Administrative Agent shall have received payment and/or reimbursement of the Administrative Agent’s and its affiliates’
fees and out-of-pocket expenses (including, to the extent invoiced, reasonable fees, charges and disbursements of counsel for
the Administrative Agent) in connection with the Loan Documents and required to be paid pursuant to the Credit Agreement.

 

(f)          The
Administrative Agent shall have made such reallocations of each Lender’s Applicable Percentage of the Revolving Exposure
under the Credit Agreement as are necessary in order that the Revolving Exposure with respect to such Lender reflects such Lender’s
Applicable Percentage of the Revolving Exposure under the Credit Agreement as amended hereby. The Borrower hereby agrees to compensate
each Lender for any and all losses, costs and expenses incurred by such Lender in connection with the assignment of any Eurocurrency
Loans and the reallocation described in this clause (f), in each case on the terms and in the manner set forth in Section 2.16
of the Credit Agreement.

 

    	2

    	 

    

 

3.            Representations
and Warranties of the Loan Parties. Each Loan Party hereby represents and warrants as follows: 

 

(a)          This
Amendment and the Credit Agreement as modified hereby constitute legal, valid and binding obligations of such Loan Party and are
enforceable against such Loan Party in accordance with their terms except to the extent that enforcement may be limited by applicable
bankruptcy, reorganization, moratorium, insolvency and similar laws affecting creditors’ rights generally or by equitable
principles of general application, regardless of whether considered in a proceeding in equity or at law.

 

(b)          As
of the date hereof and after giving effect to the terms of this Amendment, (i) the representations and warranties of the Loan
Parties set forth in the Loan Documents, as amended hereby, are true and correct in all material respects (or, in the case of
any representation or warranty qualified by materiality or Material Adverse Effect, in all respects) with the same effect as though
made on and as of the date of this Amendment (it being understood and agreed that any representation or warranty which by its
terms is made as of a specified date shall be required to be true and correct only as of such specified date) and (ii) no Default
or Event of Default has occurred and is continuing.

 

4.            Reference
to and Effect on the Credit Agreement.

 

(a)          Upon
the effectiveness hereof, each reference to the Credit Agreement in the Credit Agreement or any other Loan Document shall mean
and be a reference to the Credit Agreement as amended hereby.

 

(b)          Each
Loan Document and all other documents, instruments and agreements executed and/or delivered in connection therewith shall remain
in full force and effect.

 

(c)          Except
with respect to the subject matter hereof, the execution, delivery and effectiveness of this Amendment shall not operate as a
waiver of any right, power or remedy of the Administrative Agent or the Lenders, nor constitute a waiver of any provision of the
Credit Agreement, the Loan Documents or any other documents, instruments and agreements executed and/or delivered in connection
therewith.

 

(d)          This
Amendment is a Loan Document under (and as defined in) the Credit Agreement.

 

5.            Consent
and Reaffirmation. Without in any way establishing a course of dealing by the Administrative Agent or any Lender, each of
the undersigned Loan Parties consents to the Amendment and reaffirms the terms and conditions of the Credit Agreement, the Security
Agreement, the Pledge Agreement and any other Loan Document executed by it and acknowledges and agrees that the Credit Agreement,
the Security Agreement, the Pledge Agreement and each and every such Loan Document executed by the undersigned in connection with
the Credit Agreement remains in full force and effect and is hereby reaffirmed, ratified and confirmed.

 

6.            Governing
Law. This Amendment shall be governed by and construed in accordance with the internal laws (and not the law of conflicts)
of the State of New York.

 

7.            Headings.
Section headings in this Amendment are included herein for convenience of reference only and shall not constitute a part of this
Amendment for any other purpose.

 

    	3

    	 

    

 

8.            Counterparts.
This Amendment may be executed by one or more of the parties hereto on any number of separate counterparts, and all of said counterparts
taken together shall be deemed to constitute one and the same instrument. Delivery of an executed counterpart of a signature page
of this Amendment by telecopy, e-mailed.pdf or any other electronic means that reproduces an image of the actual executed signature
page shall be effective as delivery of a manually executed counterpart of this Amendment.

 

[Signature
Pages Follow]

 

    	4

    	 

    

 

IN WITNESS
WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered by their respective authorized officers
as of the day and year first above written. 

	 	 	 	 	 
	 	ACETO CORPORATION,	 
	 	as the Borrower	 
	 	 	 	 	 
	 	By:	/s/ Salvatore J. Guccione	 
	 	Name: 	Salvatore J. Guccione	 
	 	Title:	Chief Executive Officer	 
	 	 	 	 	 
	 	ACETO AGRICULTURAL CHEMICALS CORPORATION,	 
	 	as a Loan Party	 
	 	 	 	 	 
	 	By:	/s/ Steven Rogers	 
	 	Name:	Steven Rogers	 
	 	Title:	President	 
	 	 	 	 	 
	 	RISING PHARMACEUTICALS, INC.,	 
	 	as a Loan Party	 
	 	 	 	 	 
	 	By:	/s/ Douglas Roth	 
	 	Name:	Douglas Roth	 
	 	Title:	Vice President, Treasurer & Secretary	 
	 	 	 	 	 
	 	PACK PHARMACEUTICALS, LLC,	 
	 	as a Loan Party	 
	 	 	 	 	 
	 	By:	/s/ Douglas Roth	 
	 	Name:	Douglas Roth	 
	 	Title:	Vice President, Treasurer & Secretary	 

 

Signature
Page to Amendment No. 1 to

Credit Agreement dated as of April 30, 2014

Aceto Corporation

 

    	 

    	 

    

 

	 	 	 	 	 
	 	JPMORGAN CHASE BANK, N.A.,
	 	individually as a Lender, as the Swingline Lender,
    as an
	 	Issuing Bank and as Administrative Agent
	 	 	 	 
	 	By:	 	 
	 	Name:	 
	 	Title:	 

 

Signature
Page to Amendment No. 1 to

Credit Agreement dated as of April 30, 2014

Aceto Corporation

 

    	 

    	 

    

 

	 	 	 	 	 
	 	WELLS FARGO BANK, NATIONAL ASSOCIATION,
	 	individually as a Lender and as an Issuing Bank
	 	 	 	 
	 	By:	 	 
	 	Name:	 	 
	 	Title:	 	 

 

Signature
Page to Amendment No. 1 to

Credit Agreement dated as of April 30, 2014

Aceto Corporation

 

    	 

    	 

    

 

	 	 	 	 	 
	 	CITIBANK, N.A.,
	 	as a Lender
	 	 	 	 
	 	By:	 	 
	 	Name:	 	 
	 	Title:	 	 

 

Signature
Page to Amendment No. 1 to

Credit Agreement dated as of April 30, 2014

Aceto Corporation

 

    	 

    	 

    

 

ANNEX
A

 

SCHEDULE
2.01

 

Commitments 

	 	 	 	 	 
		 	 	REVOLVING	 
	LENDER	 	 	COMMITMENT	 
	 	 	 	 	 
	JPMORGAN CHASE BANK, N.A.	 	$	31,730,769.24	 
	 	 	 	 	 
	WELLS FARGO BANK, NATIONAL ASSOCIATION	 	$	31,730,769.24	 
	 	 	 	 	 
	CITIBANK, N.A.	 	$	11,538,461.54	 
	 	 	 	 	 
	AGGREGATE COMMITMENTS	 	$	75,000,000.00EX10_16

 Exhibit 10.16 
  

 
 DIRECTOR COMPENSATION POLICY 

Effective upon the effectiveness of the registration statement for the initial public offering of Arcadia Biosciences, Inc., a Delaware
corporation (the “Company”), directors of the Company that are not employees of the Company (“Non-Employee Directors”) shall receive the following compensation for their service as a member of the
Board of Directors (the “Board”) of the Company: 
 Cash Compensation 

Annual Retainer for Board Service 

Each Non-Employee Director shall be entitled to an annual cash retainer of Forty Thousand Dollars (US$40,000) (the “Annual
Retainer”), payable quarterly in arrears, subject to such director’s continued service to the Company as a Non-Employee Director on the last day of the preceding quarter. Such amounts shall be prorated in the case of service for
less than the entire quarter. 
 Annual Retainer for Chairman of the Board 

In addition to the Annual Retainer, the Non-Employee Director serving as the Chairman of the Board shall receive an additional annual cash
retainer of Twenty Thousand Dollars (US$20,000) (the “Chairman Annual Retainer”), payable quarterly in arrears, subject to such director’s continued service to the Company as the Chairman of the Board on the last day of
the preceding quarter. Such amounts shall be prorated in the case of service for less than the entire quarter. 
 Annual Retainer for
Board Committee Chairpersons 
 In addition to the Annual Retainer, a Non-Employee Director who serves as Chair of the Company’s
Audit Committee, Compensation Committee or Nominating and Governance Committee shall be entitled to an additional annual cash retainer equal to Fifteen Thousand Dollars (US$15,000) (in the case of the Chair of the Audit Committee), Ten Thousand
Dollars (US$10,000) (in the case of the Chair of the Compensation Committee), and/or Seven Thousand Five Hundred Dollars (US$7,500) (in the case of the Chair of the Nominating and Governance Committee), irrespective of the number of committees on
which such director serves as Chair or as a member (collectively the “Chair Retainers”). Chair Retainers shall be payable quarterly in arrears, subject to such director’s continued service to the Company as a Chair of a
committee on 

  
 1 of 3 

 
the last day of the preceding quarter. Such amounts shall be prorated in the case of service for less than the entire quarter. 

Annual Retainer for Service on a Board Committee 

In addition to the Annual Retainer, other than the Chair, each Non-Employee Director who serves as member of the Company’s Audit
Committee, Compensation Committee or Nominating and Governance Committee shall be entitled to an additional annual cash retainer equal to Seven Thousand Five Hundred Dollars (US$7,500) (in the case of a member of the Audit Committee), Five Thousand
Dollars (US$5,000) (in the case of a member of the Compensation Committee), and/or Three Thousand Seven Hundred Fifty Dollars (US$3,750) (in the case of a member of the Nominating and Governance Committee), irrespective of the number of committees
on which such director serves as Chair or as a member (collectively the “Committee Membership Retainers”). Committee Membership Retainers shall be payable quarterly in arrears, subject to such director’s continued
service to the Company as a member of a committee on the last day of the preceding quarter. Such amounts shall be prorated in the case of service for less than the entire quarter. 

Equity Award 
 Initial Award
for New Directors 
 On the date a new Non-Employee Director becomes a member of the Board, each such Non-Employee Director shall
automatically, without further action by Board or Committee, receive an option (an “Initial Option”) to purchase 15,000 shares of the common stock of the Company (each, a “Share”). The per share
exercise price for the Initial Option shall be equal to the fair market value for a Share on the date of grant. The Initial Option shall vest and becomes exercisable in three equal annual installments, with one-third of the Shares subject to the
Initial Option vesting on each of the first three anniversaries of the date of grant, subject to such director’s continued board service through each applicable vesting date. An employee director who ceases to be an employee, but who remains a
director, will not receive the Initial Equity Awards. For the avoidance of doubt, no Initial Options will be granted to existing members of the Board in connection with the closing of the initial public offering of the Company. 

Annual Award for Continuing Board Members 

At each Company’s annual meeting of stockholders, all Non-Employee Directors shall automatically, without further action by Board or
Committee, receive an option (an “Annual Option”) to purchase 5,000 Shares. The per share exercise price for the Annual Option shall be equal to the fair market value for a Share on the date of grant. The Annual Option shall
vest and becomes exercisable on the earlier of (x) the one year anniversary of the date of grant of the Annual Option and (y) the date of the Company’s next annual meeting of stockholders following the date of grant, subject to such
director’s continued board service through such vesting date. 
 Provisions Applicable to All Equity Awards 

Each Initial Option and Annual Option shall be subject to the terms and conditions of the Company’s 2015 Omnibus Equity Incentive Plan
(the “2015 Equity Plan”) and the terms of the 

  
 2 of 3 

 
Stock Option Agreement entered into by the Company and such director in connection with such award. For purposes of this Director Compensation Policy, “Fair Market Value”
shall have the meaning as set forth in the 2015 Equity Plan. Furthermore, all vesting for any such equity awards to Non-Employee Directors shall terminate, and all such equity awards shall be fully vested, upon a “Change in
Control” as defined in the 2015 Equity Plan. 
 Expense Reimbursement 

The Company shall reimburse each director, consistent with the Company’s travel and expense reimbursement policies and practices, for all
reasonable out-of-pocket expenses incurred by any director of the Company directly in connection with travel to and from any meetings of the Board or committees thereof. The Company shall make expense reimbursements to all directors within a
reasonable amount of time following submission by the director of reasonable written substantiation for the expenses. 
 Effective Date:
May 14, 2015 

  
 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]